Ergocryptine

Ergocryptine

SCHEMBL78951

CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 1.00
MAPT P10636 10/20 1.00
CYP3A4 P08684 9/20 1.00
MEN1 O00255 8/20 1.00
KMT2A Q03164 8/20 1.00
ALDH1A1 P00352 7/20 1.00
CYP2C9 P11712 7/20 1.00
HIF1A Q16665 7/20 1.00
ABCB1 P08183 7/20 1.00
HPGD P15428 5/20 1.00
USP2 O75604 5/20 1.00
LMNA P02545 5/20 1.00
ADRA2A P08913 5/20 1.00
DRD1 P21728 5/20 1.00
DRD3 P35462 5/20 1.00
HSD17B10 Q99714 4/20 1.00
CYP2C19 P33261 4/20 1.00
NPSR1 Q6W5P4 4/20 1.00
DRD2 P14416 4/20 1.00
ADRA2B P18089 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ergocryptine SCHEMBL30498875 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocryptine SCHEMBL29372991 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocryptine SCHEMBL28072302 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocryptine SCHEMBL29376491 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocryptine SCHEMBL11034170 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocryptine SCHEMBL12481541 0.98 KDM4E (0.95) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL30449023 0.94 MAPT (0.88) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocristine SCHEMBL29386896 0.93 MAPT (0.89) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocristine SCHEMBL30957132 0.92 CYP2C9 (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Ergocristine SCHEMBL14029486 0.92 CYP2C9 (1.00) KDM4EMAPTCYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026043908-A1 COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS ALLTECH, INC. (US) 2026-02-26 WO claimed
EP-4220161-A1 A BUFFER SYSTEM FOR PARTICLE-BASED MULTIPLEXED IMMUNOASSAYS Bundesrepublik Deutschland, vertreten durch den Bundesminister für Wirtschaft und Energie (DE) 2023-08-02 EP claimed
CN-115578347-A Quantitative analysis method, system and equipment for LHI cerebral edema based on deep learning 河北医科大学第二医院 2023-01-06 CN claimed
US-20200222386-A1 AGENT FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE KYOTO UNIVERSITY (JP) 2020-07-16 US claimed
EP-3646872-A1 AGENT FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE Kyoto University (JP) 2020-05-06 EP claimed
CN-102026618-B parenteral formulations of dopamine agonists 维罗科学有限责任公司 2017-07-14 CN claimed
EP-1881853-B1 ALL-OVER COATING OF VESSEL STENTS HEMOTEQ AG (DE) 2016-09-28 EP claimed
CN-105879035-A METHODS AND SYSTEMS FOR TREATMENT OF MIGRAINES AND OTHER INDICATIONS 战略科学与技术有限责任公司 2016-08-24 CN claimed
CN-103517708-B Pharmaceutical composition Kozateko Briksk (HR) 2016-02-17 CN claimed
US-20150031719-A1 Topical Therapy for the Treatment of Migraines, Muscle Sprains, Muscle Spasms, Spasticity and Related Conditions AFGIN PHARMA LLC 2015-01-29 US claimed
WO-2000012075-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-03-09 WO claimed
WO-1997027749-A1 NITROSATED AND NITROSYLATED α-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES NITROMED, INC. (US) 1997-08-07 WO claimed
US-5573776-A Oral osmotic device with hydrogel driving member ALZA CORPORATION (US) 1996-11-12 US claimed
US-5468486-A Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1995-11-21 US claimed
EP-0251732-B1 PROCESS FOR THE PREPARATION OF 2-HALOGENATED ERGOLINE DERIVATIVES RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1993-04-28 EP claimed
US-4816587-A Process for the preparation of 2-halogenated ergoline derivatives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1989-03-28 US claimed
US-4697017-A Process for the preparation of 2-bromo-α-ergocryptine RICHTER GEDEON VEGYESZETI GYAR RT (HU) 1987-09-29 US claimed
US-4609731-A Process for brominating ergot alkaloids SANDOZ LTD. (CH) 1986-09-02 US claimed
US-4390625-A ERGOCORNINE AND ERGOCRYPTINE RICHTER GEDEON VEGYESZETI GYAR RT (HU) 1983-06-28 US claimed
US-4202897-A IMIDAZON2,1-AE ISOINDOLES AND ISOQUINOLINES SANDOZ, INC. (US) 1980-05-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200222386-A1 AGENT FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE PSEN1, APP, PSEN2 KDM4E 4134/4885MAPT 6/4885CYP3A4 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.